🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

RecruitingPhase 3Ages 0 Years - 18 YearsAllYizhuo Zhang
NCT06836492 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. 0 years \< age \< 18 years old, regardless of gender; 2. Tumor patients diagnosed by histopathology or bone marrow cytology; 3. Patients are treated for the first time; 4. ECoG score ≤ 2; 5. The expected survival time is more than 8 months; 6. Patient's parent or guardian signs informed consent. Exclusion Criteria: 1. Combined with immunodeficiency disease 2. Second tumor
💊

What it tests

  • VAC，VAC/VII，CAV/IE
📍

Where

1 site
Suying Lu
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy